Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Immutep Ltd IMMP

Healthcare Biotechnology
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also... see more

Recent & Breaking News (NDAQ:IMMP)

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

GlobeNewswire December 22, 2025

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace

GlobeNewswire December 16, 2025

Immutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa

GlobeNewswire December 8, 2025

Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium

GlobeNewswire December 2, 2025

Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025

GlobeNewswire November 13, 2025

Immutep Receives A$4.6 million R&D Tax Incentive from French Government

GlobeNewswire November 3, 2025

Immutep Quarterly Activities Report Q1 FY26

GlobeNewswire October 29, 2025

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

GlobeNewswire October 20, 2025

Two Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer

GlobeNewswire October 20, 2025

Immutep Announces Successful Completion of FDA Project Optimus Requirements

GlobeNewswire October 13, 2025

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer

GlobeNewswire October 9, 2025

Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti

GlobeNewswire September 22, 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

GlobeNewswire September 8, 2025

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1

GlobeNewswire August 5, 2025

Immutep Quarterly Activities Report Q4 FY25

GlobeNewswire July 30, 2025

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

GlobeNewswire July 29, 2025

Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

GlobeNewswire July 28, 2025

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

GlobeNewswire June 23, 2025

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

GlobeNewswire May 27, 2025

Immutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

GlobeNewswire May 15, 2025

Podcasts